Engineered immune cells take on deadly brain tumors
Disease control
Terminated
This early-stage trial tests a personalized cell therapy called IL13Rα2 CAR-T for people with recurrent grade 4 glioma, an aggressive brain cancer. The treatment involves collecting a patient's immune cells, engineering them to target a protein on tumor cells, and infusing them b…
Phase: PHASE1 • Sponsor: Yang Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC